AFG1L

Across TCGA pan-cancer cohorts, AFG1L mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of AFG1L’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where AFG1L mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types AFG1L is over-expressed in tumor, although a few such as CCRCC and HNSC show the opposite, repressed pattern.

CCRCC, HNSC, and LSCC are the cancer types where AFG1L tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in AFG1L mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	III,IV	−1.196	<.001	12	view →
HNSC	All	IV	−0.493	<.001	11	view →
LSCC	Female	II,III,IV	−0.464	<.001	9	view →
COAD	Female	II,III,IV	+0.513	<.001	6	view →
PDAC	Female	II,III,IV	−0.646	<.001	5	view →
LUAD	Male	III,IV	−0.229	.036	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

AFG1L–CCRCC

Open the CCRCC breakdown →